

Roberto Carmagnani Pestana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2941663/publications.pdf>

Version: 2024-02-01

28
papers

852
citations

687363

13
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

1296
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	329.8	132
2	IL-6–Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages. <i>Journal of Immunology</i> , 2014, 192, 349-357.	0.8	110
3	Hepatocellular Carcinoma Immunotherapy. <i>Annual Review of Medicine</i> , 2022, 73, 267-278.	12.2	86
4	Histology-agnostic drug development – considering issues beyond the tissue. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 555-568.	27.6	60
5	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	7.0	54
6	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1390-1395.	3.4	54
7	Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. <i>Annals of Oncology</i> , 2018, 29, 2396-2398.	1.2	52
8	Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. <i>Oncologist</i> , 2018, 23, 1282-1288.	3.7	46
9	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104523.	1.5	38
10	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
11	Moving Beyond 3+3: The Future of Clinical Trial Design. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e133-e144.	3.8	33
12	Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. <i>Oncotarget</i> , 2020, 11, 1186-1201.	1.8	27
13	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. <i>Cancers</i> , 2019, 11, 1283.	3.7	19
14	Clinical and prognostic significance of circulating levels of angiotensin-1 and angiotensin-2 in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 37721-37732.	1.8	16
15	Systemic Options for Malignant Peripheral Nerve Sheath Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 33.	3.0	16
16	Precision Oncology in Sarcomas: Divide and Conquer. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	3.0	14
17	Consequences of the Implementation of the Model for End-stage Liver Disease System for Liver Allocation in Brazil. <i>Transplantation Proceedings</i> , 2013, 45, 2111-2114.	0.6	12
18	Impact of tissue-agnostic approvals for patients with sarcoma. <i>Trends in Cancer</i> , 2022, 8, 135-144.	7.4	11

#	ARTICLE	IF	CITATIONS
19	Basket Trials: Review of Current Practice and Innovations for Future Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 3520-3528.	1.6	10
20	Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 860453.	2.8	9
21	Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification. <i>Clinical Colorectal Cancer</i> , 2021, 20, 350-353.	2.3	5
22	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	2.0	4
23	The face mask as an established symbol against COVID-19. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1318-1319.	0.7	3
24	Diagnostic difficulty in Peutz-Jeghers syndrome. <i>Journal of Coloproctology</i> , 2015, 35, 067-071.	0.1	2
25	Changes in the Care Setting of First Consults to Palliative and Supportive Care Over a Seven-Year Period. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 86-92.	1.2	2
26	Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Oncotarget</i> , 2021, 12, 756-766.	1.8	2
27	An Observational Study of Circulating Plasma and Serum Insulin-Like Growth Factor 1 as Prognostic Biomarkers in Surgical Hepatocellular Carcinoma Patients. <i>Surgery, Gastroenterology and Oncology</i> , 2019, 24, 73.	0.1	2
28	Budd-Chiari Syndrome after Bilateral Nephrectomy for Polycystic Kidney Disease in a Kidney Transplant Recipient. <i>Urologia Internationalis</i> , 2020, 104, 330-332.	1.3	0